Stock Analysis

An Intrinsic Calculation For Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) Suggests It's 45% Undervalued

SHSE:600566
Source: Shutterstock

Key Insights

  • The projected fair value for Hubei Jumpcan Pharmaceutical is CN¥47.98 based on 2 Stage Free Cash Flow to Equity
  • Hubei Jumpcan Pharmaceutical is estimated to be 45% undervalued based on current share price of CN¥26.58
  • Analyst price target for 600566 is CN¥52.36, which is 9.1% above our fair value estimate

Does the September share price for Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.

We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

Check out our latest analysis for Hubei Jumpcan Pharmaceutical

Is Hubei Jumpcan Pharmaceutical Fairly Valued?

We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. In the first stage we need to estimate the cash flows to the business over the next ten years. Seeing as no analyst estimates of free cash flow are available to us, we have extrapolate the previous free cash flow (FCF) from the company's last reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:

10-year free cash flow (FCF) forecast

2025 2026 2027 2028 2029 2030 2031 2032 2033 2034
Levered FCF (CN¥, Millions) CN¥2.30b CN¥2.15b CN¥2.07b CN¥2.03b CN¥2.03b CN¥2.04b CN¥2.06b CN¥2.10b CN¥2.14b CN¥2.19b
Growth Rate Estimate Source Est @ -10.55% Est @ -6.53% Est @ -3.72% Est @ -1.75% Est @ -0.37% Est @ 0.60% Est @ 1.27% Est @ 1.75% Est @ 2.08% Est @ 2.31%
Present Value (CN¥, Millions) Discounted @ 6.8% CN¥2.2k CN¥1.9k CN¥1.7k CN¥1.6k CN¥1.5k CN¥1.4k CN¥1.3k CN¥1.2k CN¥1.2k CN¥1.1k

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥15b

The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.8%.

Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CN¥2.2b× (1 + 2.9%) ÷ (6.8%– 2.9%) = CN¥57b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥57b÷ ( 1 + 6.8%)10= CN¥29b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CN¥44b. In the final step we divide the equity value by the number of shares outstanding. Compared to the current share price of CN¥26.6, the company appears quite good value at a 45% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.

dcf
SHSE:600566 Discounted Cash Flow September 9th 2024

The Assumptions

We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Hubei Jumpcan Pharmaceutical as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.8%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

SWOT Analysis for Hubei Jumpcan Pharmaceutical

Strength
  • Earnings growth over the past year exceeded the industry.
  • Debt is not viewed as a risk.
  • Dividends are covered by earnings and cash flows.
  • Dividend is in the top 25% of dividend payers in the market.
Weakness
  • Earnings growth over the past year is below its 5-year average.
Opportunity
  • Annual earnings are forecast to grow for the next 3 years.
  • Good value based on P/E ratio and estimated fair value.
Threat
  • Annual earnings are forecast to grow slower than the Chinese market.

Next Steps:

Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Can we work out why the company is trading at a discount to intrinsic value? For Hubei Jumpcan Pharmaceutical, we've put together three important elements you should explore:

  1. Risks: As an example, we've found 1 warning sign for Hubei Jumpcan Pharmaceutical that you need to consider before investing here.
  2. Future Earnings: How does 600566's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the SHSE every day. If you want to find the calculation for other stocks just search here.

Valuation is complex, but we're here to simplify it.

Discover if Hubei Jumpcan Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.